StockData
Arvinas, Inc. logo

Arvinas, Inc. (ARVN) stock

ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30
$6.82+0.05 (+0.74%)

Close on Nov 17, 2026Market cap $445.93MP/E 42.6Yield –

Arvinas price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Arvinas's price to sales ratio was 1.4× on Nov 11, 2026, against 2.9× a year earlier. Over the last 5 years it ranged from 1.2× to 196.0×, with a median of 11.1×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.4×−1.3
2025Dec 31, 20252.7×−11.6
2024Jan 31, 202414.3×+0.1
2023Dec 29, 202314.2×−0.2
2022Dec 30, 202214.4×−148.5
2021Dec 31, 2021162.8×+23.7
2020Dec 31, 2020139.1×+106.4
2019Dec 31, 201932.7×+29.2
2018Dec 31, 20183.5×–

More Arvinas figures

See a number that looks wrong?